title: FDA licenses first biologic product to prevent hepatitis B reinfection in liver transplant patients.
authors.forename: Les
authors.initials: L
authors.lastname: Lang
mesh_terms: D017277:Drug Approval; D006509:Hepatitis B / Q000517:prevention & control* / Q000601:surgery*; D006801:Humans; D016031:Liver Transplantation; D055502:Secondary Prevention